ResearcherUniversity of AntwerpActive in the last 2 years

Laura Gehrcken

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-0216-9208; OpenAlex author ID A5034327750. Sources: OpenAlex.

Their work

Papers: 1
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 5

Papers, trials and grants by year

2026: 1 paper

Papers 1

IL-15 boosts mesothelin- and CD70-CAR NK cell potency in PDAC without added benefit from dual targeting. Co-author DOI 10.1016/j.omton.2026.201316 ↗

Closest collaborators

The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Christophe Deben · 1 shared paper, 2026 · strength 0.22
- Paper IL-15 boosts mesothelin- and CD70-CAR NK cell potency in PDAC without added benefit from dual targeting. DOI 10.1016/j.omton.2026.201316 ↗
Hans Prenen · 1 shared paper, 2026 · strength 0.22
- Paper IL-15 boosts mesothelin- and CD70-CAR NK cell potency in PDAC without added benefit from dual targeting. DOI 10.1016/j.omton.2026.201316 ↗
Evelien Smits · 1 shared paper, 2026 · strength 0.22
- Paper IL-15 boosts mesothelin- and CD70-CAR NK cell potency in PDAC without added benefit from dual targeting. DOI 10.1016/j.omton.2026.201316 ↗
Jonas R.M. Van Audenaerde · 1 shared paper, 2026 · strength 0.22
- Paper IL-15 boosts mesothelin- and CD70-CAR NK cell potency in PDAC without added benefit from dual targeting. DOI 10.1016/j.omton.2026.201316 ↗
Geert Roeyen · 1 shared paper, 2026 · strength 0.22
- Paper IL-15 boosts mesothelin- and CD70-CAR NK cell potency in PDAC without added benefit from dual targeting. DOI 10.1016/j.omton.2026.201316 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.